940 related articles for article (PubMed ID: 16227402)
1. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling.
Martin KA; Merenick BL; Ding M; Fetalvero KM; Rzucidlo EM; Kozul CD; Brown DJ; Chiu HY; Shyu M; Drapeau BL; Wagner RJ; Powell RJ
J Biol Chem; 2007 Dec; 282(49):36112-20. PubMed ID: 17908691
[TBL] [Abstract][Full Text] [Related]
3. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
O'Reilly KE; Rojo F; She QB; Solit D; Mills GB; Smith D; Lane H; Hofmann F; Hicklin DJ; Ludwig DL; Baselga J; Rosen N
Cancer Res; 2006 Feb; 66(3):1500-8. PubMed ID: 16452206
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
Thimmaiah KN; Easton J; Huang S; Veverka KA; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2003 Jan; 63(2):364-74. PubMed ID: 12543789
[TBL] [Abstract][Full Text] [Related]
6. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
7. Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2.
Rui L; Fisher TL; Thomas J; White MF
J Biol Chem; 2001 Oct; 276(43):40362-7. PubMed ID: 11546773
[TBL] [Abstract][Full Text] [Related]
8. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
Yan H; Frost P; Shi Y; Hoang B; Sharma S; Fisher M; Gera J; Lichtenstein A
Cancer Res; 2006 Feb; 66(4):2305-13. PubMed ID: 16489035
[TBL] [Abstract][Full Text] [Related]
9. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin.
Takano A; Usui I; Haruta T; Kawahara J; Uno T; Iwata M; Kobayashi M
Mol Cell Biol; 2001 Aug; 21(15):5050-62. PubMed ID: 11438661
[TBL] [Abstract][Full Text] [Related]
10. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
[TBL] [Abstract][Full Text] [Related]
12. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.
Shi Y; Hsu JH; Hu L; Gera J; Lichtenstein A
J Biol Chem; 2002 May; 277(18):15712-20. PubMed ID: 11872747
[TBL] [Abstract][Full Text] [Related]
13. Muscarinic-receptor-mediated inhibition of insulin-like growth factor-1 receptor-stimulated phosphoinositide 3-kinase signalling in 1321N1 astrocytoma cells.
Batty IH; Fleming IN; Downes CP
Biochem J; 2004 May; 379(Pt 3):641-51. PubMed ID: 14769130
[TBL] [Abstract][Full Text] [Related]
14. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation.
Tzatsos A; Kandror KV
Mol Cell Biol; 2006 Jan; 26(1):63-76. PubMed ID: 16354680
[TBL] [Abstract][Full Text] [Related]
15. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.
Tremblay F; Gagnon A; Veilleux A; Sorisky A; Marette A
Endocrinology; 2005 Mar; 146(3):1328-37. PubMed ID: 15576463
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
Song K; Cornelius SC; Reiss M; Danielpour D
J Biol Chem; 2003 Oct; 278(40):38342-51. PubMed ID: 12876289
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor I induces preferential degradation of insulin receptor substrate-2 through the phosphatidylinositol 3-kinase pathway in human neuroblastoma cells.
Kim B; van Golen CM; Feldman EL
Endocrinology; 2005 Dec; 146(12):5350-7. PubMed ID: 16150916
[TBL] [Abstract][Full Text] [Related]
18. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
[TBL] [Abstract][Full Text] [Related]
19. Defining the role of TORC1/2 in multiple myeloma.
Maiso P; Liu Y; Morgan B; Azab AK; Ren P; Martin MB; Zhang Y; Liu Y; Sacco A; Ngo H; Azab F; Quang P; Rodig SJ; Lin CP; Roccaro AM; Rommel C; Ghobrial IM
Blood; 2011 Dec; 118(26):6860-70. PubMed ID: 22045983
[TBL] [Abstract][Full Text] [Related]
20. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
